EIP Pharma to initiate in 2Q 2023 a Phase 2b clinical study, funded in part by a $21 million grant from the National Institute of Aging
Licences should enable potentially millions of people living in areas most impacted by HIV to access this innovative prevention medicine through low-cost generic manufacturers
She was the CEO of Tata Insights and Quants a Division of the Tata Industries Ltd.
Projected ~US$100 million cash balance of combined company expected to fund operations through mid-2025 and to clinical data over the next 12 to 24 months
She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.
The issue with a face value of Rs 10 per equity share consists of a fresh issue of equity shares worth up to Rs 400 crore
The company will not receive any proceeds from the offer as all of it will go to the promoter selling shareholder.
The JUST 100 is the only ranking that recognizes companies doing right by all their stakeholders as defined by the American public.
To create leading company developing medicines targeting metalloenzymes
The company is one of the most profitable companies manufacturing speciality chemicals in India
Subscribe To Our Newsletter & Stay Updated
